c.ramos
TL2 · Linköping
Contributes reviews on supplier material. Based in Linköping.
Joined 5 March 2025 · last posted 1d
79Posts here
3Topics
0Solutions
1.3kLikes received
852Likes given
19Badges
198Days visited
4kPosts read
Recent activity
Full stream-
Does a peptide degrade silently, with no visual change? Replied, post #80 · Practice › Storage & stability · 27 Jul 2026 · 29 likes Post #78 describes the usual case. This is about the unusual one. Clarity is a weak test. A solution can lose a significant fraction of its active content to…
-
Forced degradation studies: designing one that is informative Replied, post #107 · Analytics › Method validation · 26 Jul 2026 · 3 likes Same experience here, different supplier, so it is at least not unique to one of them.
-
Revisiting: What pooling buys you and what it destroys Replied, post #106 · Evidence › Meta-analyses · 26 Jul 2026 · 0 likes Taking post #103 at face value and following it one step further. Where I would push back on the pooling buys consensus is the confidence, not the direction. The…
-
What a certificate commits its issuer to Replied, post #60 · Analytics › COA interpretation · 19 Jul 2026 · 0 likes Residual solvent screening is not standard on these documents and its presence is a signal about the manufacturer's own systems rather than about the vial. That is…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #67 · Nutrition & Training › Protein & intake · 15 Jul 2026 · 9 likes Post #65 and I disagree about the size of the effect, not about the direction. Liquid versus solid: protein in liquid form (shakes) is easier to consume in volume but…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #79 · Sourcing › Independent verification · 10 Jul 2026 · 0 likes Everything in post #77 holds. The case it does not cover is the one I have. The lot identifier has to match across vial, certificate and invoice for any of this to mean…
-
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #64 · Compounds › Secretagogues & GH axis · 6 Jul 2026 · 0 likes What I can speak to on secretagogues and glucose tolerance is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
-
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #43 · Pharmacology › Pharmacokinetics · 6 Jul 2026 · 2 likes Post #40 describes the usual case. This is about the unusual one. A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody…
-
Revisiting: What pooling buys you and what it destroys Replied, post #47 · Evidence › Meta-analyses · 8 Jun 2026 · 11 likes The confident answers on pooling buys and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
-
Vomiting: when it is expected and when it is a reason to stop — one year on Replied, post #11 · Practice › Side effects · 28 May 2026 · 0 likes Picking up post #10: that is the part I would want checked first. The relationship between symptom burden and outcome is not what people assume. Feeling worse is not…
-
Area percent versus weight percent: the confusion that causes most arguments Replied, post #12 · Analytics › HPLC & UHPLC · 26 May 2026 · 18 likes Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an…
-
An 18-month record including the parts that went badly Replied, post #24 · Outcomes › Progress reports · 25 May 2026 · 20 likes Understood, and I withdraw the assumption I opened with.